<SEC-DOCUMENT>0001140361-20-016440.txt : 20200721
<SEC-HEADER>0001140361-20-016440.hdr.sgml : 20200721
<ACCEPTANCE-DATETIME>20200721073530
ACCESSION NUMBER:		0001140361-20-016440
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200721
FILED AS OF DATE:		20200721
DATE AS OF CHANGE:		20200721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		201037680

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>nt1003010x6_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;" align="center"><font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</font></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES
      AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Washington,
      D.C. 20549</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM
      6-K</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13A-16 OR 15D-16 UNDER</div>
    <div style="text-align: center; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">For the month of July 2020</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Commission File Number: 001-38283</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">InflaRx
      N.V.</div>
    <div style="text-align: center; color: #000000;">(Translation of registrant's name into English)</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Winzerlaer Str. 2</div>
    <div style="text-align: center; font-weight: bold;">07745 Jena, Germany</div>
    <div style="text-align: center;">(Address of principal executive office)</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
    <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div><br>
    </div>
    <div>Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
    <div><br>
    </div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div><br>
    </div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFLARX N.V.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">On July 21, 2020, InflaRx N.V. issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference
      herein.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div><br>
    </div>
    <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
      thereunto duly authorized.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2eb34cd09af64401bc593163b8ef59be" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-weight: bold;">INFLARX N.V.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 44%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div>Date: July 21, 2020</div>
          </td>
          <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
            <div>By:</div>
          </td>
          <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Niels Riedemann</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div>Niels Riedemann</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 6%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 44%; vertical-align: top;">
            <div>Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zccbe01365f424b45bd093b8ec781ba2f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Exhibit No.</div>
            </div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold;">Description</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div><a href="nt10013010x6_ex99-1.htm">99.1</a></div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: bottom;">
            <div>Press Release, dated July 21, 2020</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nt10013010x6_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.1</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><img src="nt100130106x6_ex99-1img001.jpg" height="50" width="159"></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">InflaRx
      Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia</div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z885f56537733446c9b1d4f0efebc439e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 17.85pt; vertical-align: top; align: right;">
              <div>&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z88dd560ae8da43d8be4cb2cbd9e89ec4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 17.85pt; vertical-align: top; align: right;">
              <div>&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">Subject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III part of the trial will be initiated</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z670d763f1ff24a34a9a3a1a99399e42b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 17.85pt; vertical-align: top; align: right;">
              <div>&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify;">Primary endpoint of the planned Phase III part to be 28-day all-cause mortality</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">Jena, Germany, 21 July 2020 </font>&#8211; InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,
      announced today that the Company has decided to continue development with IFX-1 in severe COVID-19 induced pneumonia.&#160; The Company plans to initiate a double-blinded, randomized, placebo-controlled Phase III trial that will be adequately powered for
      statistical analyses.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">In the Phase III part of the study, subject to regulatory approval, the Company plans to enroll approximately 360 early intubated, critically ill patients with COVID-19 induced pneumonia. InflaRx plans to conduct the
      study at sites in the US, Europe, South America and potentially other regions. An interim analysis is currently planned after enrollment of 180 patients, with the potential for an early stop for efficacy or futility. In addition to the primary
      endpoint of 28-day all-cause mortality, other planned key endpoints include assessments of organ support and assessment of disease improvement on the ordinal scale.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Dr. Korinna Pilz, Global Head of Clinical R&amp;D at InflaRx, noted: &#8220;Data from the initial exploratory Phase II part of the study in patients with severe COVID-19 induced pneumonia suggested a positive impact of IFX-1
      treatment on the all-cause mortality rate and other endpoints. Based on these encouraging results, we are excited to initiate the Phase III part of the trial, which we anticipate starting in the coming months.&#8221;</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;"><img src="nt100130106x6_ex99-1img001.jpg" height="50" width="159"></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Phase II part of the study evaluated IFX-1 treatment plus best supportive care compared to best supportive care alone for up to 28 days. The Phase II part was randomized and enrolled a total of 30 patients. The
      28-day all-cause mortality rate was 13% (n = 2 out of 15) in the IFX-1 treatment arm compared to 27% (n = 4 out of 15) in the best supportive care arm. All deaths in the best supportive care arm occurred in COVID-19 induced multi-organ failure. In
      the IFX-1 treatment arm, one patient died after an acute ventilator tube complication (leakage) leading to hypoxia and one patient who met an exclusion criterion with a history of severe chronic obstructive pulmonary disease, which was not known at
      time point of enrollment, died of pulmonary failure. In the IFX&#8209;1 treatment arm, fewer patients experienced renal impairment assessed by estimated glomerular filtration rates and more patients showed reversal of blood lymphocytopenia and a greater
      lowering of lactate dehydrogenase concentrations as a sign of reduction in tissue damage. A temporary, but statistically significant increase of D-dimer levels in the first days following IFX-1 administration was noted, as a potential signal for
      induction of blood clot lysis. No statistically significant group differences on the chosen primary endpoint of relative change (%) from baseline to day 5 in oxygenation index (defined as PaO2/FiO2 ratio) were detected.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Phase II results have been submitted for publication to a peer-reviewed medical journal along with a preprint server.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">About IFX-1:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
      Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven
      tissue and organ damage by specifically blocking C5a as a key &#8220;amplifier&#8221; of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have
      been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum and
      COVID-19 induced pneumonia.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;"><img src="nt100130106x6_ex99-1img001.jpg" height="50" width="159"></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">About InflaRx N.V.:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a
      is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann
      Arbor, MI, USA. For further information please visit www.inflarx.com.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Contacts:</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">InflaRx N.V.</div>
    <div style="text-align: justify;">Jordan Zwick &#8211; Global Head of Business Development &amp; Corporate Strategy</div>
    <div style="text-align: justify;">Email: jordan.zwick[at]inflarx.de</div>
    <div style="text-align: justify;">Tel: +1 917-338-6523</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">MC Services AG</div>
    <div style="text-align: justify;">Katja Arnold, Laurie Doyle, Andreas Jungfer</div>
    <div style="text-align: justify;">Email: inflarx[at]mc-services.eu</div>
    <div style="text-align: justify;">Europe: +49 89-210 2280&#160;&#160; US: +1-339-832-0752</div>
    <div><br>
    </div>
    <div style="text-align: justify;">FORWARD-LOOKING STATEMENTS</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
      &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; and similar expressions. Forward-looking statements appear in a number of places throughout this release and may
      include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, including the planned continuation into
      a Phase III part trial in patients with severe COVID-19 pneumonia; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future
      collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial
      functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the
      industry or us and the risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in InflaRx&#8217;s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and
      involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
      forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information
      becomes available in the future, except as required by law.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nt100130106x6_ex99-1img001.jpg
<TEXT>
begin 644 nt100130106x6_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !T 6T# 2(  A$! Q$!_\0
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MZ;\ -*GTJSFOM2U"&\D@1IXTV820J"P&5Z YKQ#0=/75_$6F::[E$O+N*!F
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MO*\KS=WR;MV,,1UP/2O%Z[/Q!K3:=HUKH%L3'.D"+=,O&T[1E0??J?\ ZYH
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M7/ ']23@ #DD@#FOD_XA^-IO''B1KT+)%80CR[2!VR57NQ XW,>3CV&3@&A
MCDJMZ7I\VK:O9Z;;E1-=SI!&6Z!F8*,^W-5*]B^ WA-[W6IO$]PF+>RW0VW/
MWIF7YC]%5N_=QCI3&?0<<:0Q)%$BI&BA551@ #H!3Z\N^,FL>*?#5E8ZQH.I
MR6]H6,%S$(HW"L>4;YE)&?F!YQPO')KQ_P#X6]X[_P"@^_\ X#0__$4K$V/K
M&BOFOP9\7/$\OC+2H=:U8W&G3SB&:-HHHQ\_RABP48"DANO:OHR^O;;3;"XO
MKR40VUO&9)9#T50,D\4@,CQEXLL_!GAR;5KM&E((C@A4X,LASA<]AP23V /!
MZ'Y$UC5KS7=8NM4OY3)=7,A=V[#T ] !@ =@ *WOB#XVN/&_B-[P^;'80YCL
M[=S_ *M.Y('&YL9/7L,D 5R=,98L;&ZU._@L;*%IKFX<1Q1KU9CTKZJ^'_PZ
ML/!NA>1<+#>:C<$/=3%,KD=%3/\ ",GGJ<D\< 8?PD^&T?ANPCUS5;<G6KA,
MHDB_\>B$= .SD=3U ^7CYL^I4,&%>(7UP+S4+FZ"[1-*TF/3))KV+5[@VNC7
MLZN$>.!RK'LV#C]<5XK2$%>P^&;<6OAK3XPV[,0DS_O?-_6O((XWFE2*-2SN
MP55'4D]!7N<<:0Q)%&H5$4*JCL!T% %/6;@VFB7TXD\MD@<HV>C8X_7%>+5Z
MGXYN!#X9DC(R9Y$C'MSN_P#9:\LIB"M'2].NM>U80(Y,DA+RRMSM'=C^?YFL
MZO5_!^CC2]%21UQ<7($DF>P_A'X _F30!-I_A72+"#R_L<=PY^]).H<G\^!^
M%<'XSTVVTS7=EJGEQS1"4H.BDD@X]!QT]Z]6KR_QY<+-XD,:@@P0I&WN>6_D
MPI#.8KK_ (>1L=:N9 /E6W*D^Y9<?R-<A7H/PYMV6TO[DXV2.L8^J@D_^A"F
M([:O#KJX>[O)KF0 /-(TC =,DYKU_P 07"VOA^_E9BO[AE4C^\1@?J17C5(8
M5[%X?LXK?P]81B,<PJYW#G+#<?U)KR*V@>ZNH;>/&^5PBY]2<"O<@ !@# %,
M!GE1_P#/-?RI]%%(#BOB-<,ME8VV!MDD:0GOE0!_[,:\]KJ_B!<"77HXE?(A
M@4,O]UB2?Y;:Y2F(ZGP#;K-XA:5E)\F!F4^A)"_R)KTQW2*-I)&5$0%F9C@
M#J37%?#FW9;:_N2!M=TC4]\J"3_Z$*O^.M2-GH@MHV(DNVV<$@[!RW]!]":0
MSA?$&M2ZWJ;SDL(%.V&,_P *_P")ZG_ZPK*HK2T#3?[6UJWM"#Y9;=(1GA1R
M?IGI]2*8CI/"7A);E$U+4HR8B=T,+#A_]IAZ>@[_ $Z^@(BQHJ(H5%&%51@
M>@H551 JJ%51@ #  I:0SC/B+<!=.LK7;S)*9,^FT8_]G_2O.ZZOQ_>>?KL=
MLKDK;Q %>P9N3^FVN4IB.H\!6ZS>(C(P/[B%G4^YPO\ )C7I]<1\.;=EM[^Y
M(&UW2-3WR 2?_0A75:OJ"Z1HE_J3H76SMI+AD!QN"*6Q^E(9\@^-=0.J>.-<
MO1<?:$DO9?*ESD-&&(3'MM"@>P%85%%44=5X3^(.L^#+:X@TA+-?M#AY7EAW
M,V!@#.>@YX]S6_)\<_&CQLJS64;$<.ML,CZ9)'Z5YR\,L00R1N@<;E+*1N'J
M*90!M^(/%VO^*9$;6M4FN@GW(SA(U/J$4!<\]<9K$IR*&=5+A 3@LV<#W..:
M]W\(? S1[FUM-4U363J5O-&LJ16:F.-L\X+GYB"/0*12$>8^!_ 6J>-]36.V
M1H;"-\7-XR_)&.I _O-CH/<9P.:^L=*TNST32K;3=/@6"UMT"1HH[>I]23DD
M]R2:DL;"TTRRCL["VAMK6($)%"@55R<G 'J23^-6*0C+\1Z';^)/#M_H]R0(
M[N(INQG8W56QD9VL <>U?&5]97&G:A<V-TGEW%M*T,J9!VNI((R.#R.U?<-?
M._Q[\,&RU^V\101GR+]1%.0"0)D& 2>@W(!@?[!--#1X_7HWQ!^*-WXMT?3-
M*MY)([=;>-]0PNP7%Q@$C _@4]!W/..%-><T4QA7N?P7^&YW1>*]:M?EX?3H
M91U])B/_ $'/^]_=-<S\)_AK)XJOTUC4TV:+;2<*PYNG'\ _V!_$>_0=ROTW
MT&!28F%%%%(1S?CFX6'PQ+&P),\B1KCL<[OY*:\LKT#XC7#K;V%L"-CN\C#O
ME0 /_0C7G],1K>&;8W7B73XPVW;*),X_N?-C]*]AKS/X?VXEUZ29H\B& E6_
MNL2!_+=7IE(9PWQ&N&$-A;!AM9GD9?<8 /ZM7 UU'CVX6;Q'Y:YS!"J-]3EO
MY,*Y>F(TO#^GC4]=M+5AF-GW2 YP5')''J!C\:]EK@?AU9YFO;YE8;5$*'L<
M\M^(POYUWU(85XWXBN&N?$6H2,02)F08]%^4?H!7L$\R6\$D\AQ'&I=CZ #)
MKPUF+,68DL3DD]Z $KU3P1;K!X8A<9W3.\C9]<[?Y**\KKVO2K=K32+.W=0K
MQP(K@?W@!G]:8C%\>7!A\--& ")YDC/MU;_V6O+J[KXC7 WV%L'Y >1D_( _
MHU<+0!L^%+=;KQ/8HV<*_F<>J@L/U KUZO./AY;L^L7-QM!2.#;GT9B,?H#7
MH](8444UW6-&=R%5022>PH \@\3W'VKQ-J$FW;B4QX_W?E_I633Y97FF>61M
MSNQ9CZD]:93$>J>![=8/#$+C.9Y'D;/KG;_)17+_ ! NO.UV*W60E8(1E?[K
M$DG]-M=]I%NUKHUE;N@1XX$5U'9L#/ZYKS/QG_R-E[_P#_T!:0S!KMOAS;HU
MU?W)SYD:)&.>,,23_P"@BN)KTCX>(@T6Y< ;S<$$]\!5Q_,TQ'7TV21(HFDD
M8(B LS,<  =2:=7)>.]8^QZ:-/B?$]U]_!Y6/OW[GCW&ZD,\_P!2O6U'4[F\
M;/[Z0L 3D@=A^ P/PJK113$>J>![=8?#$,@SF>1Y&SZYV_R45F_%F_DT_P"&
M.M212!))8T@&?X@[JK ?\!+5T^C0&VT.QA*;&6! RXQAL#/ZYKRW]H34(XO"
M^E:<2PEN+PS+CH5C0@Y_&1:0T?.]* 6( !)/  I*Z+P%82:GX_T&VCC$F;V.
M1T/0HC;W_P#'5-44?6]MH]E!H-OHKP)/90VZ6WES*&5T50H!!Z\"OECXE^#&
M\%^*I+:%6_LZY!FLW(. N>4R>I4\=2<;2>M?6U>?_&+PPOB+P+<7$48-[IF;
MJ%L#)4#]XN>N"O.!U*K20D?*]>T_ CQI)!J#^%+V5F@G#2V.YB?+< ET'' 8
M9;J "I[M7BU3V5Y/I]];WMK)Y=Q;RK+$^ =KJ<@X/'4=Z8S[AHK)\,Z]!XG\
M-6&LVPVI=1!BF2=CCAUR0,X8$9QSC-:U22%>.?'7Q=I<6B-X718[G4IG25^
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M*LJ9S@D'H<$9!Z$=P36[X^\:W?C;Q%)>2-(EC$2EG;L?]6GJ0.-S8!)Y[#.
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DCM+Z6&$8 VH51\>_S.QY]:]/HHJ20HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
